1. |
Wang MK, Yue HY, Cai J, et al. COVID-19 and the digestive system: A comprehensive review. World J Clin Cases, 2021, 9(16): 3796-3813.
|
2. |
Corso CR, Mulinari Turin de Oliveira N, Maria-Ferreira D. Susceptibility to SARS-CoV-2 infection in patients undergoing chemotherapy and radiation therapy. J Infect Public Health, 2021, 14(6): 766-771.
|
3. |
Ansari RM, Baker P. Identifying the predictors of COVID-19 infection outcomes and development of prediction models. J Infect Public Health, 2021, 14(6): 751-756.
|
4. |
Boglione L, Olivieri C, Rostagno R, et al. Role of the early short-course corticosteroids treatment in ARDS caused by COVID-19: A single-center, retrospective analysis. Adv Med Sci, 2021, 66(2): 262-268.
|
5. |
Maniscalco M, Fuschillo S, Ambrosino P, et al. Preexisting cardiorespiratory comorbidity does not preclude the success of multidisciplinary rehabilitation in post-COVID-19 patients. Respir Med, 2021, 184: 106470.
|
6. |
Haeusler KG, Kirchhof P, Kunze C, et al. Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): A randomised, open-label, multicentre study. Lancet Neurol, 2021, 20(6): 426-436.
|
7. |
Krasnow MR, Litt HK, Lehmann CJ, et al. Cancer, transplant, and immunocompromising conditions were not significantly associated with severe illness or death in hospitalized COVID-19 patients. J Clin Virol, 2021, 140: 104850.
|
8. |
Piñero P, Marco De La Calle FM, Horndler L, et al. Flow cytometry detection of sustained humoral immune response (IgG+IgA) against native spike glycoprotein in asymptomatic/mild SARS-CoV-2 infection. Sci Rep, 2021, 11(1): 10716.
|
9. |
王文辰, 夏彦明, 朱建飞, 等. 血管紧张素转换酶 2 在人类高致病性冠状病毒肺炎中作用的研究进展. 中国胸心血管外科临床杂志, 2020, 27(5): 588-596.
|
10. |
Acharya A, Lynch DL, Pavlova A, et al. ACE2 glycans preferentially interact with SARS-CoV-2 over SARS-CoV. Chem Commun (Camb), 2021, 57(48): 5949-5952.
|
11. |
SeyedAlinaghi S, Mehrtak M, MohsseniPour M, et al. Genetic susceptibility of COVID-19: A systematic review of current evidence. Eur J Med Res, 2021, 26(1): 46.
|
12. |
Calò LA, Rigato M, Sgarabotto L, et al. ACE2 and SARS-CoV-2 infection risk: Insights from patients with two rare genetic tubulopathies, Gitelman's and Bartter's Syndromes. Front Med (Lausanne), 2021, 8: 647319.
|
13. |
Kim KH, Choi BG, Rha SW, et al. Impact of renin angiotensin system inhibitor on 3-year clinical outcomes in acute myocardial infarction patients with preserved left ventricular systolic function: A prospective cohort study from Korea Acute Myocardial Infarction Registry (KAMIR). BMC Cardiovasc Disord, 2021, 21(1): 251.
|
14. |
Marazuela M, Giustina A, Puig-Domingo M. Endocrine and metabolic aspects of the COVID-19 pandemic. Rev Endocr Metab Disord, 2020, 21(4): 495-507.
|
15. |
Rodriguez-Perez AI, Labandeira CM, Pedrosa MA, et al. Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. J Autoimmun, 2021, 122: 102683.
|
16. |
Ozbalci D. A tale of two diseases: Sarcoidosis, COVID-19 and new therapeutic options with dual RAS inhibition and tetanus-diphtheria vaccine. Med Hypotheses, 2021, 152: 110619.
|
17. |
Sackin H. Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19. Med Hypotheses, 2021, 152: 110609.
|
18. |
Wehbe Z, Hammoud SH, Yassine HM, et al. Molecular and biological mechanisms underlying gender differences in COVID-19 severity and mortality. Front Immunol, 2021, 12: 659339.
|
19. |
Raghav PK, Kalyanaraman K, Kumar D. Human cell receptors: Potential drug targets to combat COVID-19. Amino Acids, 2021, 53(6): 813-842.
|
20. |
Herman-Edelstein M, Guetta T, Barnea A, et al. Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system. Cardiovasc Diabetol, 2021, 20(1): 90.
|
21. |
Fang L, Zhao W, Ye B, et al. Combination of immune checkpoint inhibitors and anti-angiogenic agents in brain metastases from non-small cell lung cancer. Front Oncol, 2021, 11: 670313.
|
22. |
Simko F, Baka T. Angiotensin-converting enzyme inhibitors and angiotensin Ⅱ receptor blockers: Potential allies in the COVID-19 pandemic instead of a threat? Clin Sci (Lond), 2021, 135(8): 1009-1014.
|
23. |
Zhao M, Wang R, Yu Y, et al. Efficacy and safety of angiotensin-converting enzyme inhibitor in combination with angiotensin-receptor blocker in chronic kidney disease based on dose: A systematic review and meta-analysis. Front Pharmacol, 2021, 12: 638611.
|
24. |
Yang LJ, Chen RH, Hamdoun S, et al. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding. Phytomedicine, 2021, 87: 153591.
|
25. |
Lozahic C, Maddock H, Sandhu H. Anti-cancer therapy leads to increased cardiovascular susceptibility to COVID-19. Front Cardiovasc Med, 2021, 8: 634291.
|
26. |
Cheng Q, Zhou L, Zhou J, et al. ACE2 overexpression inhibits acquired platinum resistance-induced tumor angiogenesis in NSCLC. Oncol Rep, 2016, 36(3): 1403-1410.
|
27. |
Feng Y, Wan H, Liu J, et al. The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol Rep, 2010, 23(4): 941-948.
|
28. |
Górecki I, Rak B. The role of microRNAs in epithelial to mesenchymal transition and cancers; focusing on mir-200 family. Cancer Treat Res Commun, 2021, 28: 100385.
|
29. |
Qian YR, Guo Y, Wan HY, et al. Angiotensin-converting enzyme 2 attenuates the metastasis of non-small cell lung cancer through inhibition of epithelial-mesenchymal transition. Oncol Rep, 2013, 29(6): 2408-2414.
|
30. |
Monari C, Sagnelli C, Maggi P, et al. More severe COVID-19 in patients with active cancer: Results of a multicenter cohort study. Front Oncol, 2021, 11: 662746.
|
31. |
Zong Z, Wei Y, Ren J, et al. The intersection of COVID-19 and cancer: Signaling pathways and treatment implications. Mol Cancer, 2021, 20(1): 76.
|
32. |
Keewan E, Beg S, Naser SA. Anti-TNF-α agents modulate SARS-CoV-2 receptors and increase the risk of infection through Notch-1 signaling. Front Immunol, 2021, 12: 641295.
|
33. |
Mahmood TB, Chowdhury AS, Hossain MU, et al. Evaluation of the susceptibility and fatality of lung cancer patients towards the COVID-19 infection: A systemic approach through analyzing the ACE2, CXCL10 and their co-expressed genes. Curr Res Microb Sci, 2021, 2: 100022.
|
34. |
Ren P, Gong C, Ma S. Evaluation of COVID-19 based on ACE2 expression in normal and cancer patients. Open Med (Wars), 2020, 15(1): 613-622.
|
35. |
Zhang H, Quek K, Chen R, et al. Expression of the SAR2-CoV-2 receptor ACE2 reveals the susceptibility of COVID-19 in non-small cell lung cancer. J Cancer, 2020, 11(18): 5289-5292.
|
36. |
Lu L, Liu X, Jin R, et al. Potential roles of the renin-angiotensin system in the pathogenesis and treatment of COVID-19. Biomed Res Int, 2020, 2020: 7520746.
|
37. |
Malkani N, Rashid MU. SARS-COV-2 infection and lung tumor microenvironment. Mol Biol Rep, 2021, 48(2): 1925-1934.
|
38. |
Singh MK, Mobeen A, Chandra A, et al. A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection? Comput Biol Med, 2021, 130: 104219.
|
39. |
de Loyola MB, Dos Reis TTA, de Oliveira GXLM, et al. Alpha-1-antitrypsin: A possible host protective factor against COVID-19. Rev Med Virol, 2021, 31(2): e2157.
|
40. |
Guney C, Akar F. Epithelial and endothelial expressions of ACE2: SARS-CoV-2 entry routes. J Pharm Pharm Sci, 2021, 24: 84-93.
|
41. |
Viveiros A, Rasmuson J, Vu J, et al. Sex differences in COVID-19: Candidate pathways, genetics of ACE2, and sex hormones. Am J Physiol Heart Circ Physiol, 2021, 320(1): H296-H304.
|
42. |
Abassi Z, Higazi AAR, Kinaneh S, et al. ACE2, COVID-19 infection, inflammation, and coagulopathy: Missing pieces in the puzzle. Front Physiol, 2020, 11: 574753.
|
43. |
Latil M, Camelo S, Veillet S, et al. Developing new drugs that activate the protective arm of the renin-angiotensin system as a potential treatment for respiratory failure in COVID-19 patients. Drug Discov Today, 2021, 26(5): 1311-1318.
|
44. |
Pironti G, Andersson DC, Lund LH. Mechanistic and therapeutic implications of extracellular vesicles as a potential link between COVID-19 and cardiovascular disease manifestations. Front Cell Dev Biol, 2021, 9: 640723.
|
45. |
Bobkova NV. The balance between two branches of RAS can protect from severe COVID-19 course. Biochem (Mosc) Suppl Ser A Membr Cell Biol, 2021, 15(1): 36-51.
|
46. |
Oz M, Lorke DE, Kabbani N. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor. Pharmacol Ther, 2021, 221: 107750.
|